**Name of Journal:** *World Journal of Hepatology*

**Manuscript NO:** 76855

**Manuscript Type:** ORIGINAL ARTICLE

***Observational Study***

**Hepatitis C virus burden: Treating and educating people without prejudice**

Merola E *et al*. HCV burden

Elettra Merola, Elisa Menotti, Giovanna Branz, Andrea Michielan, Sonia Seligmann, Annora Ratti, Flora Agugiaro, Luisa Moser, Giovanni Vettori, Anna Franceschini, William Mantovani, Riccardo Pertile, Giovanni de Pretis, Cecilia Pravadelli

**Elettra Merola, Elisa Menotti, Andrea Michielan, Sonia Seligmann, Flora Agugiaro, Luisa Moser, Giovanni Vettori, Giovanni de Pretis, Cecilia Pravadelli,** Department of Gastroenterology, Santa Chiara Hospital, Azienda Provinciale Per I Servizi Sanitari (APSS), Trento 38122, Italy

**Giovanna Branz, Annora Ratti, Anna Franceschini,** Department of SerD, Service for Drug Addiction, Azienda Provinciale Per I Servizi Sanitari (APSS), Trento 38122, Italy

**William Mantovani,** Department of Prevention, Azienda Provinciale Per I Servizi Sanitari (APSS), Trento 38122, Italy

**Riccardo Pertile,** Department of Clinical and Evaluative Epidemiology, Azienda Provinciale Per I Servizi Sanitari (APSS), Trento 38122, Italy

**Author contributions:** Elettra E and Menotti E shared the first authorship; Pravadelli C, Branz G, and Merola E designed the research and served as guarantors; Menotti E, Seligmann S, and Branz G participated in the data acquisition; Merola E, Pravadelli C, and Pertile R participated in the data analysis; all the authors participated in the interpretation of the data; Merola E, Menotti E, Pravadelli C, Branz G, and Michielan A drafted the initial manuscript; all the authors participated in a critical review of the article’s important intellectual content and approved the final version.

**Corresponding author: Andrea Michielan, MD, Doctor,** Department of Gastroenterology, Santa Chiara Hospital, Azienda Provinciale Per I Servizi Sanitari, Largo Medaglie D'oro 8, Trento 38122, Italy. andrea.michielan@apss.tn.it

**Received:** April 3, 2022

**Revised:** May 26, 2022

**Accepted:** June 22, 2022

**Published online:** July 27, 2022

**Abstract**

BACKGROUND

Hepatitis C virus (HCV) infection has a worldwide incidence of 1.1%. In Italy, 60% of people who inject drugs (PWIDs) and are receiving assistance for substance use disorder are infected with HCV. However, this subset of patients has extremely limited access to care due to multiple factors, including alcohol abuse, psychological comorbidities, and homeless status.

AIM

To describe the impact of our HCV-dedicated service for substance use disorder (SSUD) service on PWIDs receiving anti-HCV therapy.

METHODS

A dedicated, multidisciplinary team was set up at the SSUD of Trento in October 2020 to provide antiviral treatment to HCV RiboNucleic Acid-positive patients with an active or previous history of substance abuse. The treatment was followed by a health education program. Patients were treated with Direct-Acting Antivirals (DAAs). Data were retrospectively analyzed to assess the efficacy of our dedicated program in terms of therapy completion, HCV eradication, and compliance (primary endpoint). The rate of HCV reinfection and DAA-related toxicity were also assessed (secondary endpoints).

RESULTS

A total of 40 patients were enrolled in the study: 28 (70.0%) were treated with Sofosbuvir/Velpatasvir, while 12 (30.0%) received Glecaprevir/Pibrentasvir. At the time of inclusion in the study, 36 patients were receiving opioid agonist maintenance therapy, whilst another 4 had just finished the treatment. 37.5% had a history of alcoholism and 42.5% received concomitant psychiatric treatment. All 40 patients (100.0%) completed the therapy cycle and 92.5% of patients adhered to the program. All patients tested negative for viral load at the end of the treatment. There were no significant drug interactions with common psychiatric treatments and no side effects were observed. The sustained virological response was achieved in 92.5% of cases with good tolerability, although two patients discontinued treatment temporarily. After HCV eradication, one patient died from an overdose, another from complications of cirrhosis, and one reinfection occurred.

CONCLUSION

Very high adherence to therapy and good tolerability was observed in our series of HCV patients treated at the SSUD, regardless of the substance abuse condition. Further validation in a larger population is required.

**Key Words:** Hepatitis C virus; Service for substance use disorder; Direct-acting antivirals; Sustained virologic response; Compliance; Tolerability

**©The** **Author(s) 2022.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation**：Merola E, Menotti E, branz G, Michielan A, Seligmann S, ratti A, Agugiaro F, Moser L, Vettori G, franceschini A, mantovani W, Pertile R, de Pretis G, Pravadelli C. Hepatitis C virus burden: Treating and educating people without prejudice. *World J Hepatol* 2022; 14(7): 1495-1503

**URL**: <https://www.wjgnet.com/1948-5182/full/v14/i7/1495.htm>

**DOI**: https://dx.doi.org/10.4254/wjh.v14.i7. 1495

**Core Tip:** Hepatitis C virus (HCV) infection has an incidence of 1.1%, reaching 60% in Italy among people who inject drugs. This paper reports the impact of our HCV-dedicated program to provide antiviral treatment to HCV patients with a history of substance abuse. 40 patients were treated with direct-acting antivirals: 38 were receiving opioid agonist maintenance therapy, and 4 had just finished this treatment. 37.5% had a history of alcoholism, and 42.5% received concomitant psychiatric treatment. The therapy cycle was completed in all patients, and 92.5% adhered to post-therapy controls. All patients were HCV RNA-negative at the end of treatment, with a sustained virological response of 92.5%.

**INTRODUCTION**

Hepatitis C virus (HCV) infection has an incidence of around 1.1% worldwide, making it one of the main issues in the area of public health[1]. Italy has the highest prevalence of HCV-positive patients in Europe, as well as the highest rate of complication-related deaths such as cirrhosis and hepatocellular carcinoma[2]. These conditions are associated with significant costs, particularly in terms of therapies, hospital admissions, hepatic transplantations, and associated extrahepatic manifestations and complications[3-6].

Direct-Acting Antivirals (DAAs) have demonstrated a high response rate as an anti-HCV treatment, resulting in effective curative therapy in 95%-96% of cases, and is an affordable and cost-effective treatment[7].

The World Health Organization (WHO) has set ambitious targets for the global elimination of HCV, including an 80% reduction in new chronic infections, a 90% reduction in the incidence of new infections, and an 80% increase in treatment by 2030[8].

People who inject drugs (PWIDs) currently bear the heaviest burden of HCV infection in Italy, with a prevalence of around 60%, increased morbidity and mortality, and limited access to care[9]. Microelimination in this subgroup of HCV patients is becoming a public healthcare priority in order to reduce circulation[10]. According to WHO data, PWIDs account for 23% of new infections, but this population is considered “hard to reach” for several reasons. Indeed, access to care is extremely limited for these citizens due to social stigma, multifactorial frailty (*i.e.,* low compliance, alcoholic abuse, co-infection with HBV and HIV, homelessness, lack of a caregiver, and psychological and psychiatric issues), and poor use of standard medical channels[11,12].

Direct-Acting Antivirals are proven to be safe and effective in individuals with active substance abuse and those receiving opioid substitution therapy[13-15]. The SIMPLIFY study found that 92.5% of PWIDs with ongoing drug abuse achieved an overall sustained virologic response (SVR) following treatment with sofosbuvir and velpatasvir[16].

In Italy, approximately 50% of the population receiving assistance for substance use disorder is positive for HCV infection. These services in Italy could be considered a “hot spot” for HCV screening and treatment because they avoid the typical health care pattern, create a dedicated link to a care strategy for patient retention, curing the condition, and improving adherence to therapy and follow-up[11,17].

This approach would allow marginalized patients to undergo treatment in a standard care setting, accompanied throughout the whole process, thereby reducing loss to follow-up and low adherence. Since PWIDs are one of the main *reservoirs* of HCV infection, eradicating the virus in this “key subgroup” is crucial for halting its spread, improving public health, and reducing costs for the National Health System[18].

This study aims to prospectively describe the experience of our HCV-dedicated multidisciplinary program at the SSUD of Trento (Northeast Italy), which focuses on providing anti-HCV therapy in infected PWIDs with an active or past history of substance abuse.

**MATERIALS AND METHODS**

***Study design and endpoints***

This study, which had a prospective observational design and retrospective data analysis, included patients who met the following criteria: PWIDs attending our SSUD in Trento, having positive HCV-antibodies and HCV-RiboNucleic Acid (RNA) > 15 UI/mL, and were current or previous drug users.

The exclusion criteria were: age < 18 years old and the absence of informed consent.

The primary endpoint was the efficacy of our dedicated program in terms of therapy completion and PWIDs’ adherence to post-treatment controls. Secondary endpoints included HCV eradication, the rate of HCV reinfection after treatment, and DAA-related toxicity.

In compliance with local legislation, the study protocol was approved by the local ethical committee (N. A785), and patients provided their informed consent for data acquisition.

The study is reported in accordance with the STROBE guidelines for observational studies and follows the criteria of the Declaration of Helsinki.

***SSUD activities***

In October 2020, a dedicated team was set up at the SSUD in Trento to provide opioid agonist therapy and DAA therapy to HCV RNA-positive patients with an active or past history of substance abuse.

The team consists of a hepatologist, a facility physician, and four dedicated nurses. The synergistic collaboration between the different specialists resulted in the development of a health education program, which included counseling on how to avoid reinfection.

Subjects are closely guided and monitored throughout treatment and follow-up. While some patients can take the treatment on their own and only attend the SSUD once a week, the vast majority receive daily treatment directly at the SSUD or a therapeutic rehabilitation facility. The team plans and organizes all the blood tests and visits, while also monitoring and enforcing adherence.

Opioid use disorder was diagnosed following the Diagnostic and Statistical Manual of Mental Disorders 5, and its severity was assessed before and after eradication therapy. Patients were classified as: (1) “Abstinent”: The absence of other drugs other than opioid agonist maintenance therapy or occasional consumption; (2) “User”: constant use without severe impairment of health and quality of life; and (3) “Abuser”: constant consumption severely compromising health and quality of life and unable to maintain a normal social and work routine.

***Antiviral therapy***

Indications for DAA therapy followed the WHO criteria[19]. The HCV genotype was assessed before the start of treatment and the stage of liver disease was evaluated using transient elastography[20]. When this method was not feasible due to social and welfare-related reasons, liver stiffness was assessed using serum markers, such as the “Fibrosis 4 Score” (Fib-4), as recommended by the EASL Guidelines[20].

The treatment regimen was based on the standard 12-week oral schedule with Sofosbuvir/Velpatasvir or an 8-week oral Glecaprevir/Pibrentasvir regimen[20].

The patients received clinical monitoring each month throughout the treatment. Treatment efficacy was evaluated by detection of negative HCV RNA at the end of treatment and after 12 wk (SVR12), when possible, or by “delayed SVR” (SVR evaluated at any time after 12 wk).

***Statistical analysis***

Prospectively collected variables were extracted from electronic information flows and paper-based patient records and entered into an anonymous database. They included demographic information, concomitant substance abuse, comorbidities, adherence to the therapy schedule and follow-up controls, HCV RNA levels at the start and end of therapy, SVR12 or delayed SVR, rate of HCV reinfection, treatment pause, and side effects.

Statistical analysis was performed using a dedicated software program (Medcalc 15.6.1, www.medcalc.be).

The distribution of continuous variables was reported as the median and range.

SVR rates were evaluated through intention-to-treat analysis (considering all missing data as failures).

**RESULTS**

***Patient characteristics***

A total of 42 patients met this study’s inclusion criteria. The final analysis included a total of forty patients, since two patients are still undergoing treatment. Patient characteristics are detailed in Table 1.

The majority of patients were male (77.5%). Elastography for the staging of liver disease could not be used in 5 patients, and the Fib-4 score was used instead for their evaluation. Four out of 35 patients (11.4%) were already suffering from liver cirrhosis at the start of treatment: three patients were diagnosed with compensated cirrhosis (Child-Pugh A) and one was described as decompensated (Child-Pugh B7).

Twenty-eight patients (70.0%) were treated with Sofosbuvir/Velpatasvir, while 12 (30.0%) received Glecaprevir/Pibrentasvir. Table 2 reports treatment outcomes.

Recruited individuals had an active or past history of drug consumption and other psychoactive substances (*i.e.,* benzodiazepines).

Thirty-six of the 40 recruited patients were receiving opioid agonist maintenance therapy at study inclusion, whilst another 4 had just completed treatment.

A significant proportion of the study population (37.5%) had a history of alcohol consumption, whilst 42.5% received concomitant psychiatric treatment. Patients were generally prescribed benzodiazepines and neuroleptics, but six patients were prescribed selective serotonin reuptake inhibitors.

***Treatment outcomes***

Treatment outcomes are detailed in Table 2. The therapy cycle was completed by 40 patients (100%). All tested patients presented a negative viral load at the end of treatment and a sustained virologic response was observed in 92.5% (SVR12 + delayed SVR). Therapy was well-tolerated, except in two cases where the patients temporarily discontinued treatment and refused subsequent lab tests. Another patient elected to only be tested for HCV RNA at the end of treatment but refused all post-therapy controls. No significant drug interactions with commonly used psychiatric treatments or side effects were observed. One patient died of an overdose, another patient died of cirrhosis complications following HCV eradication and one reinfection was observed ten months after SVR12.

**DISCUSSION**

The present study demonstrates that a multidisciplinary, dedicated program to assist PWIDs during anti-HCV treatment can be a safe and effective method to improve their adherence to therapy and follow-up schedule. In detail, our service achieved 100% therapy completion, 92.5% adherence to post-treatment follow-up, and one loss at follow-up despite a negative HCV RNA 4 wk after treatment ended. Furthermore, 92.5% of cases responded to treatment with good tolerability of DAAs (100.0%). Therapy efficacy was also observed in people with concurrent drug and alcohol abuse, without any significant drug interactions with commonly used psychiatric treatments.

In comparison to previous studies, good adherence to treatment and the follow-up program was observed in our series, with no drop-outs due to toxicity[21-25]. In particular, Avramovic *et al*[24] reported a similar rate of virological response (92%) in PWIDs. This rate would have been even higher in our series (100.0% *vs* 96% for Avramovic *et al*[24]) if a “per-protocol” analysis had been performed by excluding any missing data or drop-outs from the calculation. Avramovic *et al*[24] also reported a high rate of loss to follow-up (17%) and reinfection (3.5%) in PWIDs with ongoing drug use treated for HCV. Adherence was higher in our series, with only one case of reinfection involving a patient who became homeless and had a history of ongoing alcohol abuse and psychiatric comorbidities. Our encouraging results are a direct outcome of the dedicated work of the SSUD of Trento’s multidisciplinary team and its efforts to increase this fragile population’s adherence to the anti-HCV program through a more vigilant and attentive approach. Adherence was difficult to maintain during the follow-up period, owing to the patients’ general condition, poor access to the healthcare system, and a low peripheral venous heritage. However, our results demonstrate that a tailored treatment and follow-up plan, accompanied by close monitoring and constant contact to avoid alienation, can also be successful in treating HCV in PWIDs.

In the SIMPLIFY multicenter design study, Cunningham *et al*[21] demonstrated high adherence to anti-HCV therapy in PWIDs, measured using an electronic blister pack. Furthermore, a correlation was observed between non-adherence and recent stimulant injecting before and during DAA therapy, but with no impact on response to therapy. Our study corroborates these findings, as loss of compliance or delayed SVR was frequently associated with deterioration in the psychological/psychiatric situation and wealth status (*i.e.,* homelessness, self-isolation, loss of job, and the absence of a caregiver). However, the two subjects who discontinued DAA therapy for an extended period due to a boost in drug abuse associated with a worsening of their psychiatric conditions may also achieve negative HCV RNA at the end of treatment.

Two subjects in our population died following SVR12, including one who began the treatment with decompensated cirrhosis (Child-Pugh B7). Our patients were predominantly young (median age 46.5 years old), male (in line with the literature[26]), and mostly without clinically significant fibrosis. Eradicating HCV in a population with a high prevalence of infection and no or early-stage liver disease has a significant impact on public health by interrupting the vicious cycle of viral spread, progression to cirrhosis, and its complications, with significant cost-effectiveness.

Despite the strength of a real-world setting and prospective design, this study has a major limitation. The findings are the result of intensive and time-consuming work, with the program having been applied to a small population on a local scale thus far. The question then becomes whether this type of model could be scaled up to a larger and more complex field while maintaining reasonable costs and demand for human resources. Based on the encouraging results achieved thus far, our next step will be to apply this multidisciplinary anti-HCV program to a larger PWID population and validate it in a larger-scale real-world setting.

**CONCLUSION**

In conclusion, targeted anti-HCV programs involving vulnerable infected patients, such as PWIDs, can be effective at improving patient compliance and eradicating infection with good tolerability. However, a larger prospective study is required to definitively confirm the efficacy of this initiative.

**ARTICLE HIGHLIGHTS**

***Research background***

Hepatitis C virus (HCV) infection has an incidence of around 1.1% worldwide, making it one of the main issues in the area of public health. Direct-Acting Antivirals (DAAs) have demonstrated a high response rate as an anti-HCV treatment, resulting in effective curative therapy in 95%-96% of cases, and is an affordable and cost-effective treatment. In Italy, approximately 50% of the population receiving assistance for substance use disorder (SSUDs) is positive for HCV infection. These services in Italy could be considered a “hot spot” for HCV screening and treatment because they avoid the typical health care pattern, create a dedicated link to a care strategy for patient retention, curing the condition, and improving adherence to therapy and follow-up.

***Research motivation***

To prospectively describe the experience of our HCV-dedicated multidisciplinary program at the SSUD of Trento (Northeast Italy), which focuses on providing anti-HCV therapy in infected "people who inject drugs" (PWIDs) with an active or past history of substance abuse.

***Research objectives***

To show the efficacy of our dedicated program in terms of therapy completion and PWIDs’ adherence to post-treatment controls. Secondary endpoints included HCV eradication, the rate of HCV reinfection after treatment, and DAA-related toxicity.

***Research methods***

This study included: PWIDs attending our SSUD in Trento, with HCV-antibodies and HCV-RiboNucleic Acid (RNA) > 15 UI/mL, with history of substance abuse. In October 2020, a dedicated team was set up at the SSUD in Trento to provide opioid agonist therapy and DAA therapy to HCV RNA-positive to these patients. The team provided health education program, including counseling, planning of blood tests and visits. Indications for DAA therapy followed the World Health Organization criteria. The HCV genotype was assessed before treatment start and the stage of liver disease by transient elastographyor Fibrosis 4 Score”, as recommended by the EASL Guidelines. The treatment regimen was based on the standard 12 wk oral schedule with Sofosbuvir/Velpatasvir or an 8 wk oral Glecaprevir/Pibrentasvir regimen. Treatment efficacy was evaluated by negative HCV RNA at the end of treatment and after 12 wk (SVR12), or by “delayed SVR” (SVR evaluated at any time after 12 wk).

***Research results***

Forty patients were included in the study, with active or past history of drug consumption and other psychoactive substances (*i.e.,* benzodiazepines), and 37.5% with history of alcohol consumption. Twenty-eight patients (70.0%) were treated with Sofosbuvir/Velpatasvir, 12 (30.0%) received Glecaprevir/Pibrentasvir. The therapy cycle was completed by 40 patients (100%). All tested patients presented a negative viral load at the end of treatment and a sustained virologic response was observed in 92.5% (SVR12 + delayed SVR). Therapy was well-tolerated, except in two cases where the patients temporarily discontinued treatment and refused subsequent lab tests. Another patient elected to only be tested for HCV RNA at the end of treatment but refused all post-therapy controls. No significant drug interactions with commonly used psychiatric treatments or side effects were observed. One patient died of an overdose and another of cirrhosis complications following HCV eradication. One reinfection was observed ten months after SVR12.

***Research conclusions***

In conclusion, targeted anti-HCV programs involving vulnerable infected patients, such as PWIDs, can be effective at improving patient compliance and eradicating infection with good tolerability. However, a larger prospective study is required to definitively confirm the efficacy of this initiative.

***Research perspectives***

Despite the strength of a real-world setting and prospective design, this study has a major limitation. The findings are the result of intensive and time-consuming work, with the program having been applied to a small population on a local scale thus far. The question then becomes whether this type of model could be scaled up to a larger and more complex field while maintaining reasonable costs and demand for human resources. Based on the encouraging results achieved thus far, our next step will be to apply this multidisciplinary anti-HCV program to a larger PWID population and validate it in a larger-scale real-world setting.

**REFERENCES**

1 **World Health Organization**. Global hepatitis report 2017. [cited 20 April 2022]. Available from: https://www.who.int/publications/i/item/9789241565455

2 **Kondili LA**, Robbins S, Blach S, Gamkrelidze I, Zignego AL, Brunetto MR, Raimondo G, Taliani G, Iannone A, Russo FP, Santantonio TA, Zuin M, Chessa L, Blanc P, Puoti M, Vinci M, Erne EM, Strazzabosco M, Massari M, Lampertico P, Rumi MG, Federico A, Orlandini A, Ciancio A, Borgia G, Andreone P, Caporaso N, Persico M, Ieluzzi D, Madonia S, Gori A, Gasbarrini A, Coppola C, Brancaccio G, Andriulli A, Quaranta MG, Montilla S, Razavi H, Melazzini M, Vella S, Craxì A; PITER Collaborating Group. Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals? *Liver Int* 2018; **38**: 2190-2198 [PMID: 29900654 DOI: 10.1111/Liv.13901]

3 **Conde I**, Vinaixa C, Berenguer M. Hepatitis C-related cirrhosis. Current status. *Med Clin (Barc)* 2017; **148**: 78-85 [PMID: 27855947 DOI: 10.1016/j.medcli.2016.09.019]

4 **Dash S**, Aydin Y, Widmer KE, Nayak L. Hepatocellular Carcinoma Mechanisms Associated with Chronic HCV Infection and the Impact of Direct-Acting Antiviral Treatment. *J Hepatocell Carcinoma* 2020; **7**: 45-76 [PMID: 32346535 DOI: 10.2147/JHC.S221187]

5 **Germani G**, Tsochatzis E, Papastergiou V, Burroughs AK. HCV in liver transplantation. *Semin Immunopathol* 2013; **35**: 101-110 [PMID: 22829333 DOI: 10.1007/s00281-012-0329-5]

6 **Cacoub P**, Comarmond C. Considering hepatitis C virus infection as a systemic disease. *Semin Dial* 2019; **32**: 99-107 [PMID: 30549107 DOI: 10.1111/sdi.12758]

7 **Martin NK**, Vickerman P, Miners A, Foster GR, Hutchinson SJ, Goldberg DJ, Hickman M. Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations. *Hepatology* 2012; **55**: 49-57 [PMID: 21898506 DOI: 10.1002/hep.24656]

8 **Scott N**, Doyle JS, Wilson DP, Wade A, Howell J, Pedrana A, Thompson A, Hellard ME. Reaching hepatitis C virus elimination targets requires health system interventions to enhance the care cascade. *Int J Drug Policy* 2017; **47**: 107-116 [PMID: 28797497 DOI: 10.1016/j.drugpo.2017.07.006]

9 **Nava FA,** Alberti A, Andreoni M, Babudieri S, Barbarini G, D’Egidio PF, Leonardi C, Lucchini A. For a program of eradication of hepatitis C in the populations at risk (drug users and convicts). *Acta Bio Medica Atenei Parmensis* 2018; **89**: 33-41 [DOI: 10.23750/abm.v89i10-S.7968]

10 **Grebely J**, Dore GJ, Morin S, Rockstroh JK, Klein MB. Elimination of HCV as a public health concern among people who inject drugs by 2030 - What will it take to get there? *J Int AIDS Soc* 2017; **20**: 22146 [PMID: 28782335 DOI: 10.7448/IAS.20.1.22146]

11 **Molinaro S**, Resce G, Alberti A, Andreoni M, D Egidio PPF, Leonardi C, Nava FA, Pasqualetti P, Villa S. Barriers to effective management of hepatitis C virus in people who inject drugs: Evidence from outpatient clinics. *Drug Alcohol Rev* 2019; **38**: 644-655 [PMID: 31441565 DOI: 10.1111/dar.12978]

12 **Kondili LA**, Aghemo A, Andreoni M, Galli M, Rossi A, Babudieri S, Nava F, Leonardi C, Mennini FS, Gardini I, Russo FP. Milestones to reach Hepatitis C Virus (HCV) elimination in Italy: From free-of-charge screening to regional roadmaps for an HCV-free nation. *Dig Liver Dis* 2022; **54**: 237-242 [PMID: 33926816 DOI: 10.1016/j.dld.2021.03.026]

13 **Hajarizadeh B**, Cunningham EB, Reid H, Law M, Dore GJ, Grebely J. Direct-acting antiviral treatment for hepatitis C among people who use or inject drugs: a systematic review and meta-analysis. *Lancet Gastroenterol Hepatol* 2018; **3**: 754-767 [PMID: 30245064 DOI: 10.1016/S2468-1253(18)30304-2]

14 **Messina V**, Onorato L, Di Caprio G, Claar E, Iovinella V, Russo A, Rosato V, Salzillo A, Nevola R, Simeone F, Curcio F, Pisaturo M, Coppola N. Directly Acting Antiviral-Based Treatment for HCV-Infected Persons Who Inject Drugs: A Multicenter Real-Life Study. *Life (Basel)* 2020; **11** [PMID: 33396802 DOI: 10.3390/Life11010017]

15 **Christensen S**, Buggisch P, Mauss S, Böker KHW, Schott E, Klinker H, Zimmermann T, Weber B, Reimer J, Serfert Y, Wedemeyer H. Direct-acting antiviral treatment of chronic HCV-infected patients on opioid substitution therapy: Still a concern in clinical practice? *Addiction* 2018; **113**: 868-882 [PMID: 29359361 DOI: 10.1111/add.14128]

16 **Grebely J**, Dalgard O, Conway B, Cunningham EB, Bruggmann P, Hajarizadeh B, Amin J, Bruneau J, Hellard M, Litwin AH, Marks P, Quiene S, Siriragavan S, Applegate TL, Swan T, Byrne J, Lacalamita M, Dunlop A, Matthews GV, Powis J, Shaw D, Thurnheer MC, Weltman M, Kronborg I, Cooper C, Feld JJ, Fraser C, Dillon JF, Read P, Gane E, Dore GJ; SIMPLIFY Study Group. Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial. *Lancet Gastroenterol Hepatol* 2018; **3**: 153-161 [PMID: 29310928 DOI: 10.1016/S2468-1253(17)30404-1]

17 **Andreoni M**, Coppola N, Craxì A, Fagiuoli S, Gardini I, Mangia A, Nava FA, Pasqualetti P. Meet-Test-Treat for HCV management: patients' and clinicians' preferences in hospital and drug addiction services in Italy. *BMC Infect Dis* 2022; **22**: 3 [PMID: 34983405 DOI: 10.1186/s12879-021-06983-y]

18 **Messina V**, Russo A, Parente E, Russo G, Raimondo T, Salzillo A, Simeone F, Onorato L, Di Caprio G, Pisaturo M, Coppola N. Innovative procedures for micro-elimination of HCV infection in persons who use drugs. *J Viral Hepat* 2020; **27**: 1437-1443 [PMID: 32810330 DOI: 10.1111/jvh.13375]

19 **Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection**. [cited 20 January 2022]. Available from: https://www.who.int/publications/i/item/9789241550345

20 **European Association for the Study of the Liver**, Clinical Practice Guidelines Panel: Chair:; EASL Governing Board representative:; Panel members:. EASL recommendations on treatment of hepatitis C: Final update of the series☆. *J Hepatol* 2020; **73**: 1170-1218 [PMID: 32956768 DOI: 10.1016/j.jhep.2020.08.018]

21 **Cunningham EB**, Amin J, Feld JJ, Bruneau J, Dalgard O, Powis J, Hellard M, Cooper C, Read P, Conway B, Dunlop AJ, Norton B, Litwin AH, Hajarizadeh B, Thurnheer MC, Dillon JF, Weltman M, Shaw D, Bruggmann P, Gane E, Fraser C, Marks P, Applegate TL, Quiene S, Siriragavan S, Matthews GV, Dore GJ, Grebely J; SIMPLIFY study group. Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY study. *Int J Drug Policy* 2018; **62**: 14-23 [PMID: 30352330 DOI: 10.1016/j.drugpo.2018.08.013]

22 **Read P**, Lothian R, Chronister K, Gilliver R, Kearley J, Dore GJ, van Beek I. Delivering direct acting antiviral therapy for hepatitis C to highly marginalised and current drug injecting populations in a targeted primary health care setting. *Int J Drug Policy* 2017; **47**: 209-215 [PMID: 28587943 DOI: 10.1016/j.drugpo.2017.05.032]

23 **Aspinall EJ**, Corson S, Doyle JS, Grebely J, Hutchinson SJ, Dore GJ, Goldberg DJ, Hellard ME. Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis. *Clin Infect Dis* 2013; **57** Suppl 2: S80-S89 [PMID: 23884071 DOI: 10.1093/cid/cit306]

24 **Avramovic G**, Reilly M, Cullen W, Macías J, McCombe G, McHugh T, Oprea C, Story A, Surey J, Sabin C, Bivegete S, Vickerman P, Walker J, Ward Z, Lambert JS. HEPCARE EUROPE- A case study of a service innovation project aiming at improving the elimination of HCV in vulnerable populations in four European cities. *Int J Infect Dis* 2020; **101**: 374-379 [PMID: 32992012 DOI: 10.1016/j.ijid.2020.09.1445]

25 **Fabbiani M**, Lombardi A, Colaneri M, Del Poggio P, Perini P, D'Ambrosio R, Degasperi E, Dibenedetto C, Giorgini A, Pasulo L, Maggiolo F, Castelli F, Brambilla P, Spinelli O, Re T, Lleo A, Rumi M, Uberti-Foppa C, Soria A, Aghemo A, Lampertico P, Baiguera C, Schiavini M, Fagiuoli S, Bruno R; NAVIGATORE-Lombardia Study Group. High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV-infected patients treated in a real-life setting. *J Viral Hepat* 2021; **28**: 558-568 [PMID: 33306247 DOI: 10.1111/jvh.13454]

26 **European Drug Report 2021**. [cited 20 January 2022]. Available from: https://www.emcdda.europa.eu/edr2021

**Footnotes**

**Institutional review board statement:** In accordance with local legislation, the study protocol was approved by the local ethical committee (N. A785), and informed consent was obtained from patients for data acquisition.

**Informed consent statement:** All study participants, or their legal guardian, provided informed written consent prior to study enrollment.

**Conflict-of-interest statement:** All authors declare that they have no conflict of interest.

**Data sharing statement:** Participants gave informed consent for data sharing

**STROBE statement:** The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** April 3, 2022

**First decision:** May 12, 2022

**Article in press:** June 22, 2022

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** Italy

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Ballestín SS, Spain; Lo SY, Taiwan **S-Editor:** Wang LL **L-Editor:** A **P-Editor:** Wang LL

**Table 1 Patient characteristics at the start of treatment**

|  |  |
| --- | --- |
| **Characteristic** | ***n* = 40** |
| Gender [male; *n* (%)] | 31 (77.5) |
| Age [yr; median (range)] | 46.5 (24-63) |
| Severity of opioid use disorder |  |
| Abstinent, *n* (%) | 16 (40.0) |
| User, *n* (%) | 21 (52.5) |
| Abuser, *n* (%) | 3 (7.5) |
| Concomitant opioid agonist maintenance therapy |  |
| Metadone, *n* (%) | 35 (87.5) |
| Buprenorfine, *n* (%) | 1 (2.5) |
| None (previous history), *n* (%) | 4 (10.0) |
| History of alcohol abuse, *n* (%) | 14 (35.0) |
| Concomitant psychoactive drugs, *n* (%) | 17 (42.5) |
| HCV genotype |  |
| 1a, *n* (%) | 21 (52.5) |
| 3, *n* (%) | 18 (45.0) |
| 4, *n* (%) | 1 (2.5) |
| Liver disease staging1 |  |
| F0, *n* (%) | 8 (22.9) |
| F1, *n* (%) | 12 (34.3) |
| F2, *n* (%) | 6 (17.1) |
| F3, *n* (%) | 5 (14.3) |
| F4, *n* (%) | 4 (11.4) |

1Available in 35 cases. Elastography could not be performed in the remaining 5 patients and disease staging was calculated using “Fibrosis 4 Score”. HCV: Hepatitis C virus.

**Table 2 Management and outcomes of anti-hepatitis C virus treatment**

|  |  |
| --- | --- |
| **Treatment outcomes** | ***n* = 40** |
| Therapy management |  |
| Self-administration at home, *n* (%) | 16 (40.0) |
| Daily administration at the SUD, *n* (%) | 21 (52.5) |
| In-patient in rehabilitation service, *n* (%) | 3 (7.5) |
| Complete adherence to the programme, *n* (%) | 37 (92.5) |
| Therapy completion, *n* (%) | 40 (100) |
| Post-treatment controls, *n* (%) | 37 (92.5) |
| HCV-RNA at end of treatment |  |
| Negative, *n* (%) | 39 (97.5) |
| Not assessed, *n* (%) | 1 (2.5) |
| SVR12 | 21 (52.5) |
| Negative, *n* (%)\* | 28 (70.0) |
| Not assessed, *n* (%) | 12 (30.0) |
| Delayed SVR |  |
| Negative, *n* (%)1 | 9 (22.5) |
| Not assessed, *n* (%) | 3 (7.5) |
| HCV reinfection, *n* (%) | 1 (2.5) |
| Side effects, *n* (%) | 0 (0) |

1Intention-to-treat analysis. SVR: Sustained Virologic response; HCV: Hepatitis C virus.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2022 Baishideng Publishing Group Inc. All rights reserved.**